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Abstract: Ligustrum lucidum Aiton and its berries have been used in Chinese traditional medicine
for around two thousand years. In the present study, L. lucidium berries harvested in two regions
of Portugal were studied. Haemolytic activity and inhibition of oxidative haemolysis as well as the
enzyme inhibitory activities (α-amylase enzyme and acetylcholinesterase) were assessed. Results
suggest that the different biological activities varied according to the region where samples were
collected. Results demonstrated that the sample obtained from region R1 was the most efficient
extract for all parameters evaluated, presenting the lowest values of IC50, 10.67 ± 0.46 µg/mL for the
inhibition of erythrocyte oxidative haemolysis, 58.28 ± 3.77 µg/mL for the α-amylase enzyme and
67.67 ± 2.10 µg/mL for the acetylcholinesterase inhibition. L. Lucidum berries may be an interesting
source of compounds for use in the development of the therapeutic armamentarium for diseases
where enzymatic disruption is believed to play a role.
Keywords: Ligustrum lucidum Aiton berries; diabetes; Alzheimer’s disease; enzyme
inhibitory potential
1. Introduction
Ligustrum lucidum Aiton is a plant that naturally occurs in hot and humid climates, namely in the
east, south and south-west of China, South Korea and India [1]. However, it has been reported to be one
of the most invasive plant species in the world, having global relevance. In ancient times, their leaves
and berries were harvested, dried and applied in the traditional medicine for several purposes, such
as premature menopause, blurred vision, cataracts, tinnitus, rheumatic pains, palpitations, backache
and insomnia [2]. Several studies were performed with the aim of characterizing the composition of
Ligustrum lucidum fruits, revealing the presence of triterpenoids, iridoids, flavones, phenolic glucosides
and other less abundant components, among which are polysaccharides, amino acids, fatty acids,
volatile components, pigments and other minor elements [3].
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Different biological activities from its berries have been studied in recent years, namely
anti-inflammatory, antitumour, antioxidant, and antiviral activities [4–6]. However, as far as the
authors know, there are no studies regarding the enzyme inhibitory potential of the berries and
very little information is available regarding L. lucidum produced in Europe, particularly in Portugal.
Changes in the enzymatic activity and pathways are involved in the pathogenic mechanisms of several
diseases: the aberrant increase activity of acetylcholinesterase is associated with Alzheimer’s disease,
while higher activity of the digestive enzyme α-amylase plays a role in obesity and type 2 Diabetes
mellitus [7].
Therefore, the aim of the present study was to evaluate the enzyme (α-amylase and
acetylcholinesterase) inhibitory potential as well as the haemolytic activity and inhibition of oxidative
haemolysis of L. lucidum berries harvested in two different Portuguese regions [Lisbon (R1) e Castelo
Branco (R2)]. These two regions are representative in terms of distribution and present different
edaphoclimate conditions, and it was decided to evaluate the effect of region on several enzymes
because we wanted to obtain a comprehensive view of the possible beneficial effects of this plant on
human health.
2. Results and Discussion
2.1. Hemolytic Activity and Inhibition of Oxidative Hemolysis
The hemolytic activity of 50% ethanol L. lucidum extract and its ability to protect
erythrocytes against hemolysis induced by the oxidizing agent 2,2′-azobis (2-methylpropionamidine)
dihydrochloride (AAPH) were evaluated.
The results obtained for the inhibition of erythrocyte oxidative hemolysis induced by L. lucidum
extracts are presented in Figures 1 and 2. It was observed that erythrocytes incubated with the
highest concentrations of extracts or ascorbic acid practically did not undergo hemolysis. However,
the addition of AAPH induced time-dependent hemolysis. The extracts significantly protected the
erythrocytes against damage caused by the oxidizing agent with IC50 values after 3 h of incubation
ranging from 10.67 ± 0.46 µg/mL (R1) to 13.48 ± 0.23 µg/mL (R2).
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Figure 1. Hemolytic activity of L. lucidum berries, from the two Portuguese regions (R1—Lisbon
and R2—Castelo Branco), incubated with erythrocytes and 0.9% NaCl solution for 240 min, without
the presence of 2,2′-azobis (2-methylpropionamidine) (AAPH). The control consists of erythrocytes
incubated only with 0.9% NaCl solution.
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Figure 2. Antioxidant activity of L. lucidum extracts in vivo with 50% ethanol, from the two Portuguese
regions in study (R1—Lisbon and R2—Castelo Branco).
Inhibition induced by ascorbic acid (AA, 99.7%) (Merck and Riedel-de Haën), positive control,
was lower (IC50 = 45.05 ± 0.23 µg/mL) and different from that obtained in the presence of the extracts.
2.2. Enzyme Inhibitory Activities
The uthors evaluated the effect of L. lucidum extr cts in the enzymatic activity of α-amylase and
acetylcholin sterase in or er to obtain a comprehensive idea of the possible beneficial effects of these
extracts in two very important groups of diseases where those enzymes play a role—neurodegenerative
and metabolic.
2.2.1. Inhibition of α-Amylase
Th inhibitio of α-amylase may delay carbo ydrate dig stion and glucose uptake with a
consequent reduc ion in postprandial blood glucose level in diabetic patients [8]. The study of this
effect is relevant, considering that more than 40% of the Portuguese population has Diabetes mellitus
or intermediate hyperglycemia. In the present study, it was found that all extracts inhibited α-amylase.
The extract from Region 1 induced the highest inhibition (IC50 of 58.28 ± 3.77 µg/mL), even below
acarbose, the positive control. The extracts from R2 were less effective (IC50 of 78.43 ± 2.50 µg/mL)
but not statistically different from the value obtained for the control (69.15 ± 1.49 µg/mL) (Figure 3).
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The concentrations of L. lucidum extracts required to induce 50% inhibition of α-amylase
were 10-fold lower than those reported by Kumar et al. [9] in medicinal plant extracts from India
(IC50 = 562.18 ± 5.98 µg/mL).
2.2.2. Inhibition of Acetylcholinesterase
Currently, Alzheimer’s disease is the leading cause of dementia and with the increasing ageing of
the population, its prevalence is expected to triple over the next decades. As such, the development
of strategies that slow or halt Alzheimer’s disease progression is imperative for improving patients’
quality of life and to reduce the attributable health care costs [10]. taking this into account, the effect of
L. lucidum extracts on the inhibition of acetylcholinesterase was evaluated.
In this study, it was observed that R1 (IC50 = 67.67 ± 2.10 µg/mL) had the highest
acetylcholinesterase inhibition, as described in the previous assay. Higher IC50 values were obtained
for R2 samples, meaning a lower acetylcholinesterase inhibition (Figure 3).
The inhibition observed for the control, Eserine, differed significantly from that obtained
using extracts.
3. Materials and Methods
3.1. Plant Samples
The broad-leaf privet berries (L. lucidum A.) used in this study were acquired in Portugal in
December 2016 and frozen at −20 ◦C until the extraction procedures were carried out. In order to
study the effect of different climatic conditions on the characteristics and biological properties of the
plants, samples from two regions (Lisbon, R1; and Castelo Branco, R2) were analysed and compared.
3.2. Extraction Conditions
The extraction procedure was performed as previously described [5]. In the previous work,
several extraction methods were tested in order to obtain the extract with the highest antioxidant
power. Three different solvents were tested: boiling water (45 min); 100% ethanol (shacked 6, 12 and
24 h) and 50% ethanol–water (v/v) (shacked 6, 12 and 24 h). All experiments were performed in
triplicate, at room temperature in the dark. MiliQ-water was used for the extraction and 96% ethanol
was purchased from Merck. The extract presenting the highest antioxidant activity was then prepared
with 50% ethanol following 15 h of stirring at 120 rpm, at room temperature. Therefore, in this study,
the extracts were prepared by mixing 20.5 g of plant with 50 mL of solvent. After this, the samples were
centrifuged at 5000 rpm for 10 min and the supernatant was transferred to a vial and stored at −20 ◦C
until further analysis. All extractions were carried out in duplicate, and all further measurements and
analysis were then carried out in triplicate. The final extract concentration was 50 mg/mL.
3.3. Antioxidant Assays in Erythrocytes
3.3.1. Preparation of Erythrocyte Suspensions
Peripheral blood samples (20 mL) were collected via jugular venipuncture from four sheep,
randomly chosen, allocated at the Polytechnic Institute of Bragança. Sheep were 2–3 years old at the
time of blood collection and were carefully examined by veterinarians in order to exclude the presence
of any signs of disease. All procedures were in agreement with the guidelines of the EU Directive
2010/63/EU (European Union, 2010) for the protection of animals used for experimental and other
scientific purposes and were approved by local Animal Care and Use Committee.
The blood was placed in tubes containing sodium citrate. Tubes were then centrifuged at 700× g
for 10 min and the blood plasma and leukocyte layer were discarded.
The erythrocytes were washed three times with 0.9% sodium chloride (NaCl—Sigma (Madrid,
Spain)) solution, and then a 10% erythrocyte suspension in 0.9% NaCl solution was prepared for the
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inhibition assays of oxidative haemolysis, determined using the method described by Campos et
al. [11].
3.3.2. Inhibition of Oxidative Haemolysis
The cells were preincubated at 37 ◦C for 30 min in the presence of different concentrations of the
extract (10 to 60 µg extract/mL). After this period, 50 mM AAPH (2,2′-azobis-2-amidinopropane Sigma
(Madrid, Spain)) solution was added. This reaction mixture was shaken gently while being incubated
at 37 ◦C for 4 h. In all experiments, a negative control (erythrocytes in PBS—Sigma (Madrid, Spain)
(erythrocytes in a phosphate buffered saline (PBS) of 150 mmol/L NaCl, 1.9 mmol/L NaH2PO4,8.1
mmol/L Na2HPO4, pH 7.4)) and extract controls (erythrocytes in PBS with each extract) were used.
The extent of haemolysis was determined spectrophotometrically (Jenway) according to a method
reported before [12]. Briefly, aliquots of the reaction mixture were taken out at each hour of the 4 h
of incubation, diluted with saline (0.9%NaCl solution), and centrifuged at 4000 rpm for 10 min to
separate the erythrocytes. The percentage of haemolysis was determined by measuring the absorbance
of the supernatant (A) at 545 nm and compared with that of complete haemolysis (B) by treating an
aliquot with the same volume of the reaction mixture with distilled water. The haemolysis percentage
was calculated using the formula:
Hemolysis(%) =
(
Abs sample
Abs total hemolysis
)
× 100 (1)
Assays were performed in triplicate, and ascorbic acid (AA, 99.7%) was used as the control.
3.4. Acetylcholinesterase Inhibition
The inhibition of acetylcholinesterase was evaluated spectrophotometrically following the method
of Ellman et al. [13] with slight modifications. Acetylcholinesterase of Electrophorus electricus (electric
ceel Type-VI-S, Sigma Chemical Co, St. Louis, MO, USA) was used. The acetylcholinesterase
activity was quantified using 15mM 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB, Sigma Chemical
Co, St. Louis, MO, USA). The hydrolysis of acetylcholine iodide was monitored by the formation the
anion 5-tio-2-methyl nitrobenzoate (yellow colour), measured at 412 nm. The percentage of inhibition
was determined by comparing the rates of reaction of samples (final concentrations of 1000, 750, 500,
250, 50, 10, 1.5 µg/mL) with those of the blank (ethanol in phosphate buffer (Merck and Riedel-de
Haën, 0.2 M, pH = 8) using the following formula, where E is the activity of enzyme without test
sample and S is the activity of enzyme with the sample under analysis:
E− S
E
× 100 (2)
The extract concentration providing 50% inhibition (IC50) was calculated by interpolation from the
graph of I% against extract concentration, following linear regression analysis with 95% of confidence
level using the standard curve built with serine (Sigma-Aldrich (Madrid, Spain)) as reference.
3.5. α-Amylase Inhibition
The assessment of α-amylase inhibition was performed as reported by Thilagam et al. [14] using
starch azure (Sigma Chemical Co, St. Louis, MO, USA) as substrate. It was dissolved (2 g) in buffer Tris
50 mM-HCl (Merck, Darmstadt, Germany) (pH 6.9) containing 10 mM CaCl2 (Merck and Riedel-de
Haën) the mixture was boiled at 100 ◦C for 5 min and preincubated at 37 ◦C for 10 min. Afterwards,
the sample dissolved in DMSO (Sigma-Aldrich, Madrid, Spain). (50%), at final concentrations of 1250,
1000, 750, 500, 250, 50 and 10 µg/mL, was added to each test. Then, 0.1 mL of α-amylase from pig
pancreas (Sigma, A-6255; 2.0 U/mL; 50 mM Tri-HCl) was added. The samples were then incubated at
37 ◦C for 10 min, after the reaction was stopped by adding 0.5 mL of acetic acid at 50%. The mixture
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was centrifuged at 2000 rpm for 5 min and the absorbance of the supernatant was measured at 595 nm.
Acarbose (Sigma-Aldrich, Madrid, Spain) was used as the positive control. α-amylase inhibition was
calculated using the following equation:
I(%) = 100−
(
B− b
A− a
)
× 100 (3)
where A is the activity without inhibitor; a is the negative control without inhibitor; B is the activity
with inhibitor; and b is the negative control with inhibitor.
The extract concentration providing 50% inhibition (IC50) was calculated by interpolation from
the graph of I% against extract concentration, following linear regression analysis with 95% of
confidence level.
3.6. Statistical Analysis
To compare the values obtained, a Least Significant Difference (LSD) test post-hoc test with 95%
confidence was applied to the corresponding variables. This test allows making a direct comparison
between two means from two individual groups; any difference larger than the LSD is considered a
significant result. The statistical analysis was performed on Statistica 13.0 software (Dell Software,
Round Rock, TX, USA).
4. Conclusions
Extracts from L. lucidum berries (prepared with 50% ethanol) from region R1 had a significantly
superior inhibitory activity for both α-amylase and acetylcholinesterase, suggesting that the biological
activities of L. lucidum berries appear to depend on their place of origin.
The interesting potential of the studied extracts to inhibit α-amylase and acetylcholinesterase
enzymes suggests that these extracts (or isolated compounds) may be useful agents for controlling
disorders where such enzymes play a role, although our results are still very preliminary. Indeed,
plant extracts contain a complex composition profile and its biological effect cannot be attributed to
one single compound. Further studies may then be performed in order to assess the absorption rate of
the compounds available in these extracts and whether these are able to cross the blood–brain barrier.
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